DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
No randomized semaglutide trial in binge eating disorder has reported results yet. A retrospective cohort study found larger drops in Binge Eating Scale scores with semaglutide than without it.
No randomized semaglutide trial in BED has reported results yet; a retrospective cohort study found larger drops in Binge Eating Scale scores with semaglutide. Lisdexamfetamine remains the FDA-approved standard.
Eating disorder specialists, academic obesity medicine. Off-label use growing in BED + obesity comorbid patients.
Eating disorder specialists must evaluate first — restrictive eating risk increases on GLP-1s if behavioral context is wrong. Not appropriate for anorexia or bulimia nervosa.
For BED + obesity, this is increasingly the off-label of choice. Coordinate with an eating disorder specialist.
Editorial summary. Off-label use is legal but not FDA-evaluated. Insurance typically does not cover off-label prescriptions. Not medical advice.